Shanghai FDA Withdraws GMP Certificates, Suspends Production Of Drug Makers As Part Of “Five Links” Program
This article was originally published in PharmAsia News
Executive Summary
SHANGAHI - Shanghai FDA withdrew two GMP certificates and suspended the production of two companies in an effort to enhance compliance by drug and device manufacturers to the "five links" program, the Shanghai government announced Dec. 10
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)